Research
Hormonal
Saturated fatty acids (e.g., palmitate) and oxidized cholesterol drive metaflammation by activating stress kinases (JNK, PKC, PKR) and inflammatory pathways (TLR4, NF-kB), which directly inhibit insulin signaling.
High intake of saturated fats and oxidized lipids can directly interfere with how your cells respond to insulin by triggering inflammatory stress signals. Reducing these specific lipid types may help maintain insulin sensitivity.
GoodSupportsHIGH confidence
Palmitate accumulation also leads to ceramide biosynthesis, which can activate inflammatory pathways and inhibit insulin action... Palmitate directly contributes to the synthesis of DAGs and ceramides... both DAGs and ceramides cause insulin resistance via inhibition of IRS1 and AKT, respectively, downstream of insulin receptor (IR).
Why this rating
Supported by multiple cited studies on molecular pathways.
Source
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment
Meric Erikci Ertunc et al. · Journal of Lipid Research · 2016
DOI 10.1194/jlr.r066514
narrative_reviewCited 480×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic nutrient excess and obesity overwhelm adipose tissue storage capacity, causing ectopic lipid accumulation in liver and muscle, which triggers lipotoxicity and metaflammation, leading to insulin resistance and metabolic disease.Good
- Inhibition of ceramide synthesis improves glucose and energy metabolism by recovering insulin signaling in liver and muscle.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →